711 related articles for article (PubMed ID: 15504997)
21. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
[TBL] [Abstract][Full Text] [Related]
22. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.
Nauck MA; Duran S; Kim D; Johns D; Northrup J; Festa A; Brodows R; Trautmann M
Diabetologia; 2007 Feb; 50(2):259-67. PubMed ID: 17160407
[TBL] [Abstract][Full Text] [Related]
23. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
Norwood P; Liutkus JF; Haber H; Pintilei E; Boardman MK; Trautmann ME
Clin Ther; 2012 Oct; 34(10):2082-90. PubMed ID: 23031623
[TBL] [Abstract][Full Text] [Related]
24. Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.
Buse JB; Han J; Miller S; MacConell L; Pencek R; Wintle M
Curr Med Res Opin; 2014 Jul; 30(7):1209-18. PubMed ID: 24621255
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
Yuan GH; Song WL; Huang YY; Guo XH; Gao Y
Chin Med J (Engl); 2012 Aug; 125(15):2677-81. PubMed ID: 22931974
[TBL] [Abstract][Full Text] [Related]
26. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
Mari A; Nielsen LL; Nanayakkara N; DeFronzo RA; Ferrannini E; Halseth A
Horm Metab Res; 2006 Dec; 38(12):838-44. PubMed ID: 17163361
[TBL] [Abstract][Full Text] [Related]
27. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
[TBL] [Abstract][Full Text] [Related]
28. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes.
Iwamoto K; Nasu R; Yamamura A; Kothare PA; Mace K; Wolka AM; Linnebjerg H
Endocr J; 2009; 56(8):951-62. PubMed ID: 19706990
[TBL] [Abstract][Full Text] [Related]
29. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
Malloy J; Capparelli E; Gottschalk M; Guan X; Kothare P; Fineman M
Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153
[TBL] [Abstract][Full Text] [Related]
30. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.
Ratner RE; Maggs D; Nielsen LL; Stonehouse AH; Poon T; Zhang B; Bicsak TA; Brodows RG; Kim DD
Diabetes Obes Metab; 2006 Jul; 8(4):419-28. PubMed ID: 16776749
[TBL] [Abstract][Full Text] [Related]
31. Clinical experience with exenatide in a routine secondary care diabetes clinic.
Natarajan B; Edavalath M; Davies J; Jenkins L; Marshall-Richards N; Evans D; Price DE; Bain SC; Stephens JW
Prim Care Diabetes; 2010 Apr; 4(1):57-60. PubMed ID: 20022310
[TBL] [Abstract][Full Text] [Related]
32. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Drucker DJ; Buse JB; Taylor K; Kendall DM; Trautmann M; Zhuang D; Porter L;
Lancet; 2008 Oct; 372(9645):1240-50. PubMed ID: 18782641
[TBL] [Abstract][Full Text] [Related]
33. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
[TBL] [Abstract][Full Text] [Related]
34. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.
Fineman MS; Bicsak TA; Shen LZ; Taylor K; Gaines E; Varns A; Kim D; Baron AD
Diabetes Care; 2003 Aug; 26(8):2370-7. PubMed ID: 12882864
[TBL] [Abstract][Full Text] [Related]
35. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide.
Pencek R; Brunell SC; Li Y; Hoogwerf BJ; Malone J
Endocr Pract; 2012; 18(2):227-37. PubMed ID: 22446132
[TBL] [Abstract][Full Text] [Related]
36. Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.
Schnabel CA; Wintle M; Kolterman O
Vasc Health Risk Manag; 2006; 2(1):69-77. PubMed ID: 17319471
[TBL] [Abstract][Full Text] [Related]
37. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin.
Liutkus J; Rosas Guzman J; Norwood P; Pop L; Northrup J; Cao D; Trautmann M
Diabetes Obes Metab; 2010 Dec; 12(12):1058-65. PubMed ID: 20977576
[TBL] [Abstract][Full Text] [Related]
38. Exenatide versus glibenclamide in patients with diabetes.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Diabetes Technol Ther; 2010 Mar; 12(3):233-40. PubMed ID: 20151774
[TBL] [Abstract][Full Text] [Related]
39. Exenatide.
Keating GM
Drugs; 2005; 65(12):1681-92; discussion 1693-5. PubMed ID: 16060703
[TBL] [Abstract][Full Text] [Related]
40. [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
Pujante Alarcón P; Hellín Gil MD; Román LM; Ferrer Gómez M; García Zafra MV; Tébar Massó J
Med Clin (Barc); 2012 Dec; 139(13):572-8. PubMed ID: 22209597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
